↓ Skip to main content

Oncotarget

Article Metrics

Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma

Overview of attention for article published in Oncotarget, December 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
4 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
19 Mendeley
Title
Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma
Published in
Oncotarget, December 2018
DOI 10.18632/oncotarget.26455
Authors

Nicholas M. Szigetvari, Deepika Dhawan, José A. Ramos-Vara, Christopher P. Leamon, Patrick J. Klein, A. Audrey Ruple, Hock Gan Heng, Michael R. Pugh, Satish Rao, Iontcho R. Vlahov, Pierre L. Deshuillers, Philip S. Low, Lindsey M. Fourez, Ashleigh M. Cournoyer, Deborah W. Knapp

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 21%
Student > Bachelor 3 16%
Student > Master 3 16%
Other 2 11%
Researcher 1 5%
Other 1 5%
Unknown 5 26%
Readers by discipline Count As %
Veterinary Science and Veterinary Medicine 4 21%
Biochemistry, Genetics and Molecular Biology 4 21%
Medicine and Dentistry 2 11%
Agricultural and Biological Sciences 1 5%
Immunology and Microbiology 1 5%
Other 2 11%
Unknown 5 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2019.
All research outputs
#7,960,694
of 14,167,291 outputs
Outputs from Oncotarget
#2,573
of 12,459 outputs
Outputs of similar age
#183,307
of 371,458 outputs
Outputs of similar age from Oncotarget
#34
of 113 outputs
Altmetric has tracked 14,167,291 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,459 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 371,458 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 113 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.